PE20080424A1 - Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas - Google Patents

Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas

Info

Publication number
PE20080424A1
PE20080424A1 PE2007001088A PE2007001088A PE20080424A1 PE 20080424 A1 PE20080424 A1 PE 20080424A1 PE 2007001088 A PE2007001088 A PE 2007001088A PE 2007001088 A PE2007001088 A PE 2007001088A PE 20080424 A1 PE20080424 A1 PE 20080424A1
Authority
PE
Peru
Prior art keywords
maleate
trifluorometil
metoxy
quinolin
difluorophenyl
Prior art date
Application number
PE2007001088A
Other languages
English (en)
Spanish (es)
Inventor
Xiaoming Chen
Xiao Chen
Jianguo Yin
Xiaoyong Fu
David J Blythin
Rongze Kuang
Ho-Jane Shue
Scott Trzaska
Chee-Wah Tang
Vicenzo Liotta
Zaher Shabani
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20080424A1 publication Critical patent/PE20080424A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2007001088A 2006-08-14 2007-08-14 Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas PE20080424A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14

Publications (1)

Publication Number Publication Date
PE20080424A1 true PE20080424A1 (es) 2008-04-28

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001088A PE20080424A1 (es) 2006-08-14 2007-08-14 Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas

Country Status (11)

Country Link
US (1) US7956189B2 (enExample)
EP (1) EP2069337A1 (enExample)
JP (3) JP2010500406A (enExample)
CN (1) CN101522671A (enExample)
AR (1) AR062373A1 (enExample)
CA (1) CA2660703A1 (enExample)
CL (1) CL2007002366A1 (enExample)
MX (1) MX2009001770A (enExample)
PE (1) PE20080424A1 (enExample)
TW (1) TW200819446A (enExample)
WO (1) WO2008021271A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006249866B2 (en) 2005-05-26 2011-10-13 Aldeyra Therapeutics, Inc. Compositions and methods of treating retinal disease
WO2011072141A1 (en) 2009-12-11 2011-06-16 Neuron Systems, Inc. Compositions and methods for the treatment of macular degeneration
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
CN117045653A (zh) 2013-01-23 2023-11-14 奥尔德拉医疗公司 与毒性醛相关的疾病和治疗
US10550085B2 (en) 2015-08-21 2020-02-04 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
AU2019319740A1 (en) * 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス, インコーポレイテッド 多形化合物およびその使用
WO2020223717A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
WO2021231792A1 (en) 2020-05-13 2021-11-18 Aldeyra Therapeutics, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2565599C (en) 2004-05-18 2012-07-31 Schering Corporation Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors

Also Published As

Publication number Publication date
WO2008021271A1 (en) 2008-02-21
CN101522671A (zh) 2009-09-02
JP2013032394A (ja) 2013-02-14
JP2012176989A (ja) 2012-09-13
TW200819446A (en) 2008-05-01
CL2007002366A1 (es) 2008-03-14
MX2009001770A (es) 2009-02-25
JP2010500406A (ja) 2010-01-07
CA2660703A1 (en) 2008-02-21
EP2069337A1 (en) 2009-06-17
AR062373A1 (es) 2008-11-05
US20080108818A1 (en) 2008-05-08
US7956189B2 (en) 2011-06-07

Similar Documents

Publication Publication Date Title
PE20080424A1 (es) Sales maleato, tosilato, fumarato y oxalato de la 5-(1(s)-amino-2-hidroxietil)-n-[(2,4-difluorofenil)-metil]-2-[8-metoxi-2-(trifluorometil)-5-quinolin]-4-oxazolcarboxamida y procesos de preparacion para las mismas
CY1121017T1 (el) Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4-[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
EA201591978A1 (ru) 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил)- карбамимидоил)пиразин-2-карбоксамид
PE20120083A1 (es) Sal monotosilato del compuesto 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2, 3-dihidro-imidazo-[4,5-c]-quinolin-1-il)-fenil]-propionitrilo en su forma cristalina a
RU2010128512A (ru) Гетероциклические ингибиторы мек и способы их применения
RU2019100065A (ru) Кристаллы анилинпиримидинового соединения, действующего в качестве ингибитора EGFR
GEP201706735B (en) Kinase inhibitors
JP2012530705A5 (enExample)
JP2011518833A5 (enExample)
PE20121337A1 (es) Forma cristalina y amorfa de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa
JP2006522118A5 (enExample)
MY151295A (en) Pyrimidyl indoline compound
CO5580767A2 (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
CY1112255T1 (el) Ενωσεις οι οποιες περιεχουν γουανιδινη που ειναι χρησιμες ως ανταγωνιστες του μουσκαρινικου υποδοχεα
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
PE20080949A1 (es) Azolilmetiloxiranos, su uso para combatir hongos fitopatogenos, asi como productos que los contienen
AR075418A1 (es) Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad.
PE20070806A1 (es) Composicion farmaceutica que comprende un derivado de diarilurea
JP2012500205A5 (enExample)
RU2009138470A (ru) Композиция для наружного применения на коже
JP2013503170A5 (enExample)
CO6270221A2 (es) "forma cristalina 2 de n-[4-(3-amino-1h-indazol-4-il)fenil]-n'-(2-fluoro-5-metilfenil)urea".
JP2008542390A5 (enExample)
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica

Legal Events

Date Code Title Description
FC Refusal